Osinusi is vice president, Clinical Research for Hepatitis, Respiratory and Emerging Viruses at Gilead.
The FDA's accelerated approval of this therapy provides the first approved treatment option for chronic hepatitis delta in the US. Anu Osinusi, MD, discusses how this targeted therapy is designed to slow disease progression and improve patient outcomes.
Therapeutic vaccines GS-2829 and GS-6779 demonstrate immune responses and strong safety profile, showing potential to contribute to global hepatitis B elimination efforts.
Multinational real-world analysis underscores the effectiveness of sofosbuvir/velpatasvir (SOF/VEL) across diverse populations and highlights the need for timely treatment initiation to improve patient outcomes.
Anu Osinusi, MD provides insights on the findings of Gilead’s investigational therapy from its phase 3 MYR301 study, which are being reported at the ongoing European Association for the Study of the Liver (EASL) Congress 2025.
Anu Osinusi, MD, discusses the findings examining bulevirtide as a standalone therapy and in combination with pegylated interferon alpha.
